BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27708433)

  • 1. Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.
    Xu WX; Wang J; Tang HP; He YP; Zhu QX; Gupta SK; Gu SH; Huang Q; Ji CN; Liu LF; Li GL; Xu CJ; Xie Y
    Sci Rep; 2016 Oct; 6():34686. PubMed ID: 27708433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope delimitation: A new method for defining epitopes of human IgG-reactive antigenic peptides based on rabbit-recognized epitope motifs.
    Tang HP; He YP; Wang J; Zhan JM; Lian WB; Xue F; Wang L; Li Y; Zhang A; Zhang F; Xu C; Li J; Xu WX
    J Med Virol; 2024 Jan; 96(1):e29388. PubMed ID: 38235845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing of Epitope-Focused Vaccine by Targeting E6 and E7 Conserved Protein Sequences: An Immuno-Informatics Approach in Human Papillomavirus 58 Isolates.
    Sabah SN; Gazi MA; Sthity RA; Husain AB; Quyyum SA; Rahman M; Islam MR
    Interdiscip Sci; 2018 Jun; 10(2):251-260. PubMed ID: 27640170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
    Uversky VN; Roman A; Oldfield CJ; Dunker AK
    J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
    Wang H; Yu JY; Li L
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
    Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
    J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prediction of B cell epitopes of human papillomavirus type 16 L1 protein].
    Wang A; Jiang M; Li N; Zhang G; Qi Y; Liu Y; Xi Y; Zhou J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Apr; 32(4):442-5. PubMed ID: 27053606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16.
    Wang A; Li N; Zhou J; Chen Y; Jiang M; Qi Y; Liu H; Liu Y; Liu D; Zhao J; Wang Y; Zhang G
    Int J Biol Macromol; 2018 Oct; 118(Pt A):1354-1361. PubMed ID: 29959021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.